TEA Synchronized With Natural Breathing for EPS
Transcutaneous Electrical Acustimulation Synchronized With Natural Breathing for Epigastric Pain Syndrome
The goal of this study is to assess the acceptance and usability as well as safety of the AutoSTEA device is in treating epigastric pain syndrome in adults. It will also explore preliminary clinical and mechanistic signals. The main questions it aims to answer are:
- Does the AutoSTEA device ease epigastric pain symptoms?
- Is the AutoSTEA device safe and feasible for patients to use at their home?
Participants will:
- Use the device for 30-60 minutes at home each day for 4 weeks
- Have a phone check-in four times through the trial (once a week).
- Answer the daily and weekly questionnaires which consist of questions regarding symptoms, device usability, and adverse events experienced.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Donovan Veccia
- 电话号码:2167783567
- 邮箱:dveccia@metrohealth.org
学习地点
-
-
Ohio
-
Cleveland、Ohio、美国、44109
- MetroHealth Medical Center
-
接触:
- Donovan Veccia
- 电话号码:216-924-6246
- 邮箱:dveccia@metrohealth.org
-
Parma、Ohio、美国、44130
- MetroHealth Parma Medical Center
-
接触:
- Donovan Veccia
- 电话号码:216-924-6246
- 邮箱:dveccia@metrohealth.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- At least 18 years of age
- Diagnosed with epigastric pain syndrome according to Rome V Criteria
- Experienced epigastric pain at least 3 days a week for at least 3 months
- Must have normal esophagogastroduodenoscopy performed in last 2 years
Exclusion Criteria:
- Any history of gastritis, gastric/duodenal ulcers, or other organic upper GI diseases
- Current drug or alcohol abuse
- Currently pregnant or planning to become pregnant
- History of major abdominal surgery
- History of severe mental illness
- Total knee-replacement surgery or above-the-knee amputation
- Any unstable or uncontrolled medical disorders
- Current use of proton pump inhibitors, anti-nausea medications, or other functional dyspepsia treatments UNLESS regimen has remained unchanged and stable over last 3 months
- Current use of anti-depressants or NSAIDs
- Having any implanted electrical devices (pacemakers, defibrillators, neurostimulators, or any other implanted electrical devices).
- Not being fluent in English
- Having prior significant experience/knowledge with acupuncture
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Treatment First Arm
This arm will receive the experimental treatment for 4 weeks. |
The AutoSTEA device is a device that detects the user's respiration wave and synchronizes each breath to deliver electrical stimulation at acupuncture points via skin surface electrodes. With this automated synchronization device, patients can inhale and exhale with an uninterrupted and normal respiration pace while receiving the TEA treatment, largely simplifying the treatment procedures, improving patients' compliance, and enhancing the effectiveness of the method. |
|
其他:Sham first arm
This arm will first receive the sham treatment for 4 weeks. |
The sham treatment is the same as the AutoSTEA device except that it doesn't synchronize with users breathing. It still does deliver the same electric shocks. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Patient's Symptom Response to the Treatment as Assessed by Functional Dyspepsia Symptom Diary
大体时间:From enrollment to the end of treatment in four weeks
|
This questionnaire will be filled out daily, and it describes the physical dyspepsia symptoms experienced by the patient in the last 24 hours. It is done on a scale from 0-10, with 0 meaning they have not experienced a symptom at all, and 10 being they have severely experienced a symptom. |
From enrollment to the end of treatment in four weeks
|
|
Patient's Symptom Response to the Treatment as Assessed by Nepean Dyspepsia Index Questionnaire
大体时间:From enrollment until the end of treatment at 4 weeks
|
Assess how well a patient's dyspepsia symptoms respond to the treatment. This will be done using the Nepean Dyspepsia Index Questionnaire. One will be filled out weekly, where patients describe how much their dyspepsia symptoms have affected their daily lives. The scale for this will be 0-4, with 0 being no effect on their daily life and 4 being extreme effect on their daily lives. |
From enrollment until the end of treatment at 4 weeks
|
|
Patient's Operating Experience with the Device as Assessed by Usability and Comfort Questionnaire
大体时间:From enrollment to the end of treatment in four weeks
|
Assess how easy the device is for patients to use in their home. This will be done using the usability questionnaire. This questionnaire will be filled out daily and the user will rate on a 0-5 scale how easy and comfortable the device was to use. 0 would signify the device being extremely difficult and extremely uncomfortable to use, while 5 would signify the device being extremely easy and extremely comfortable to use. |
From enrollment to the end of treatment in four weeks
|
|
Patient's Operating Experience with the Device when Self-Administered at Home as Assessed by the Weekly Safety and Adverse Events Questionnaire
大体时间:From enrollment to the end of treatment in four weeks
|
Assess any adverse effects the device may have when used by patients in their home. This will be done using the device safety questionnaire. The safety questionnaire is to be filled out weekly, with any adverse event that is experienced being reported. These adverse events (if applicable) will be rated in severity on a 0-5 scale, with 0 being no experienced adverse event and 5 being extremely severe (requiring medical attention). |
From enrollment to the end of treatment in four weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Assess Patient Compliance with Device as Assessed by Daily Device-Use Log
大体时间:From enrollment to the end of treatment in four weeks
|
Patients will keep a device-use log that is filled out daily. They will write how many sessions they use the device for and how long each session was. |
From enrollment to the end of treatment in four weeks
|
|
Electrogastrogram (EGG) Measure
大体时间:Once during the initial visit and once during the final visit (weeks 0 and 4).
|
The patient will undergo an EGG. The myoelectrical activity of the stomach will be measured by cycles per minute (CPM), which is the frequency of electrical slow waves generated by the smooth muscles of the stomach. A CPM of under 2.5 or above 3.75 will be considered abnormal. |
Once during the initial visit and once during the final visit (weeks 0 and 4).
|
|
Electrocardiogram (ECG) Measure
大体时间:Once during the initial visit and once during the final visit (weeks 0 and 4).
|
Patients will undergo an ECG. This will measure their heart rate variability (HRV) by tracking the interval in milliseconds between each heartbeat. What is considered normal or abnormal will vary greatly depending on the patient. |
Once during the initial visit and once during the final visit (weeks 0 and 4).
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- STUDY00000910
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.